What is the recommended androgen deprivation therapy regimen for an 80-year-old man with metastatic prostate cancer and a PSA of 185 ng/mL?

Androgen Deprivation Therapy for Metastatic Prostate Cancer in an 80-Year-Old Man

For an 80-year-old man with metastatic prostate cancer and PSA 185 ng/mL, initiate continuous androgen deprivation therapy (ADT) via LHRH agonist or antagonist combined with abiraterone acetate plus prednisone, or alternatively enzalutamide, as these combinations demonstrate superior survival and quality of life benefits compared to ADT alone.

Primary Treatment Recommendation

The foundation of treatment is continuous ADT that must be maintained indefinitely 1. This can be achieved through:

• LHRH agonists (leuprolide, goserelin)
• LHRH antagonists (degarelix)
• Bilateral orchiectomy (surgical castration)

LHRH agonists and antagonists are clinically equivalent 2. The choice between pharmaceutical and surgical castration should be discussed with the patient regarding convenience, cost, and reversibility.

Essential Combination Therapy

ADT monotherapy is no longer the standard of care for metastatic hormone-sensitive prostate cancer. The evidence strongly supports adding an androgen receptor pathway inhibitor (ARPI):

First-Line Options (Strong Evidence):

• Abiraterone acetate 1000 mg daily + prednisone 5 mg twice daily 1, 3
• Enzalutamide 160 mg daily 1, 3
• Apalutamide 240 mg daily 3, 4
• Darolutamide 600 mg twice daily 3

All four ARPIs demonstrate moderate survival benefit with low toxicity risk and strong recommendation strength 1. These agents improve both overall survival and quality of life when added to ADT.

Age-Specific Considerations for This 80-Year-Old Patient

Given the patient's age, several factors influence treatment selection:

Docetaxel Chemotherapy Decision:

Do NOT add docetaxel to the initial regimen for this 80-year-old patient unless he has:

• Excellent performance status (ECOG 0-1)
• Minimal comorbidities
• High-volume disease (visceral metastases or ≥4 bone lesions with ≥1 beyond vertebral bodies/pelvis)

The guideline explicitly states that younger, healthier men should consider docetaxel or abiraterone added to ADT, whereas older and/or unhealthier men should receive ADT 2. Docetaxel carries moderate to high toxicity risk 1, which is particularly concerning in octogenarians.

ARPI Selection in Elderly Patients:

All four ARPIs are reasonable choices. Consider:

• Abiraterone + prednisone: Requires concurrent corticosteroid (adds steroid-related risks)
• Enzalutamide: No corticosteroid required; watch for falls/cognitive effects
• Apalutamide: No corticosteroid required; monitor for falls, fractures (12% vs 6% placebo) 2
• Darolutamide: Potentially favorable toxicity profile

Disease Volume Assessment

Determine if the patient has high-volume disease (HVD) versus low-volume disease (LVD):

• HVD: Visceral metastases OR ≥4 bone lesions with ≥1 beyond vertebral bodies/pelvis
• LVD: Does not meet HVD criteria

This distinction matters because:

• HVD patients derive clear benefit from ADT + ARPI combinations 3, 4
• LVD patients also benefit from ADT + ARPI, though the magnitude may be smaller 4

Monitoring Protocol

Initial Assessment (Baseline):

• PSA level
• Testosterone level (confirm castrate level <50 ng/dL or <1.7 nmol/L)
• Complete blood count (hematocrit)
• Comprehensive metabolic panel
• Bone density scan (given ADT-related osteoporosis risk)
• Cardiac evaluation (ADT increases cardiovascular risk)

Follow-Up Schedule:

• 3-6 months after initiation: Assess PSA response, testosterone level, hematocrit, symptom control, and adverse effects 5
• Then every 3-6 months: PSA, testosterone, clinical assessment
• Annually: Hematocrit, bone density, cardiovascular assessment

Target PSA Response:

Achieving PSA ≤0.2 ng/mL by 9 months is the strongest predictor of favorable outcomes (AUC 0.87, NPV 0.97) 6. Earlier time points (3 or 6 months) have lower predictive accuracy.

Continuous vs. Intermittent ADT

For this symptomatic patient with PSA 185 ng/mL and metastatic disease, use continuous ADT 1.

Intermittent ADT may be considered only if:

• Patient becomes asymptomatic
• PSA falls to <0.2 ng/mL after 18 months of treatment 2
• Patient prioritizes quality of life over potential small survival trade-off

However, continuous ADT should be maintained indefinitely when combined with ARPIs 1, as the evidence for intermittent therapy applies primarily to ADT monotherapy, not combination regimens.

Critical Pitfalls to Avoid

1. Do not use ADT monotherapy: This is outdated and inferior to combination therapy 3, 4
2. Do not stop ADT when adding other agents: ADT must continue indefinitely regardless of additional therapies 1
3. Do not use bevacizumab, estramustine, or sunitinib: These show no benefit and excess toxicity 1
4. Monitor for hematocrit >54%: Stop therapy temporarily if this occurs, evaluate for hypoxia/sleep apnea, then reinitiate at reduced dose 5
5. Assess cardiovascular risk: ADT increases cardiovascular events, particularly concerning in elderly patients 7
6. Screen for falls risk: ARPIs, especially apalutamide, increase fracture risk 2
7. Monitor for cognitive decline: ADT can cause cognitive impairment in elderly patients 7

Bone-Directed Therapy

Initiate antiresorptive therapy (denosumab 120 mg monthly or zoledronic acid 4 mg every 3-4 weeks) to prevent skeletal-related events, as ADT accelerates bone loss 4. This is particularly important given the patient's age and metastatic bone disease.

Palliative Care Integration

Offer palliative care consultation to all patients with metastatic disease 1. This is not reserved for end-of-life but should be integrated early to optimize symptom management and quality of life.

Practical Implementation

Start immediately with:

1. LHRH agonist (e.g., leuprolide 22.5 mg IM every 3 months) OR LHRH antagonist (e.g., degarelix 240 mg SC loading, then 80 mg monthly)
2. Abiraterone 1000 mg PO daily + prednisone 5 mg PO twice daily
   • OR Enzalutamide 160 mg PO daily
3. Denosumab 120 mg SC monthly (with calcium/vitamin D supplementation)
4. Baseline laboratory and imaging studies
5. Palliative care referral

Cost consideration: Abiraterone costs approximately $11,000/month 2, similar for other ARPIs. Discuss financial toxicity and assistance programs with the patient.